Edition:
India

Akari Therapeutics PLC (AKTX.OQ)

AKTX.OQ on NASDAQ Stock Exchange Capital Market

1.87USD
11:07pm IST
Change (% chg)

$-0.10 (-5.08%)
Prev Close
$1.97
Open
$1.94
Day's High
$1.94
Day's Low
$1.87
Volume
29,256
Avg. Vol
56,472
52-wk High
$3.35
52-wk Low
$0.87

Latest Key Developments (Source: Significant Developments)

Akari Therapeutics PLC Files For Sale Of Up To 1.22 Million Ordinary Shares
Saturday, 18 Jul 2020 

July 17 (Reuters) - Akari Therapeutics PLC ::AKARI THERAPEUTICS PLC FILES FOR SALE OF UP TO 1.22 MILLION ORDINARY SHARES BY THE SELLING STOCKHOLDER - SEC FILING.  Full Article

Akari QTRLY Loss Per Share $0.00
Wednesday, 24 Apr 2019 

April 23 (Reuters) - Akari Therapeutics PLC ::AKARI REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.AKARI THERAPEUTICS PLC QTRLY LOSS PER SHARE $0.00.AKARI THERAPEUTICS PLC - AS OF DECEMBER 31, 2018, COMPANY HAD CASH OF $5.4 MILLION, AS COMPARED TO CASH OF $28.1 MILLION AS OF DECEMBER 31, 2017.  Full Article

Positive FDA Meeting Outlines Path Ahead For Akari Therapeutics’S Coversin In Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (Hsct-Tma)
Wednesday, 13 Mar 2019 

March 13 (Reuters) - Akari Therapeutics PLC ::POSITIVE FDA MEETING OUTLINES PATH AHEAD FOR AKARI THERAPEUTICS’S COVERSIN IN HEMATOPOIETIC STEM CELL TRANSPLANT-RELATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA).AKARI THERAPEUTICS PLC - HSCT-TMA TRIAL IN PEDIATRIC PATIENTS EXPECTED TO START Q4 2019 FOLLOWING RECENT FDA FEEDBACK.AKARI THERAPEUTICS PLC - HSCT-TMA TRIAL IN PEDIATRIC PATIENTS EXPECTED TO START Q4 2019 FOLLOWING RECENT FDA FEEDBACK.AKARI THERAPEUTICS PLC - FRAMEWORK FOR TRIAL DESIGN WAS AGREED TO WITH FDA.AKARI THERAPEUTICS PLC -AKARI PLANS TO COMMENCE A TRIAL IN EUROPEAN AND U.S. PEDIATRIC HSCT-TMA PATIENTS IN Q4 OF 2019.  Full Article

Akari Qtrly Loss Per Common Share $0.01
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Akari Therapeutics PLC ::AKARI ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.AKARI THERAPEUTICS PLC QTRLY LOSS PER COMMON SHARE $0.01.AKARI THERAPEUTICS - AS OF JUNE 30, 2018, HAD CASH OF $15.1 MILLION, AS COMPARED TO CASH OF $28.1 MILLION AS OF DEC 31, 2017.  Full Article

BRIEF-Aspire Capital Fund Reports 19.89% Passive Stake In Akari Therapeutics - SEC Filing

* ASPIRE CAPITAL FUND LLC REPORTS 19.89% PASSIVE STAKE IN AKARI THERAPEUTICS PLC AS OF JULY 1 - SEC FILING Source text for Eikon: https://bit.ly/3eT7bFx Further company coverage: